Oncology Archives - Page 2 of 5 - Corcept Therapeutics

The glucocorticoid receptor modulator relacorilant reverses the immunosuppressive effects of cortisol

June 6, 2023

Greenstein & Hunt • 2023 • International Immunopharmacology

Selective Glucocorticoid Receptor Modulation Reveals a New Role for CLEC10A in Patients With Solid Tumors

April 17, 2023

Mann et al. • 2023 • AACR 2023

Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators

March 28, 2023

Mallick et al • 2023 • Transl Res.

ROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer

March 26, 2023

Alexander Olawaiye et al. • 2023 • SGO Annual Meeting 2023

Phase 1 Efficacy and Pharmacodynamic Results of Exicorilant + Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

February 16, 2023

Michael Morris et al. • 2023 • ASCO GU Cancers Symposium 2023

Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant

February 15, 2023

Pivonello et al • 2022 • Front. Endocrinol.

Phase 2 Results of Relacorilant + Nab-Paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer with and Without Prior Bevacizumab

February 13, 2023

Colombo et al • 2022 • International Gynecologic Cancer Society 2022 Annual Meeting

Glucocorticoid Receptor Expression and Activity in a Phase 2 Ovarian Cancer Trial of the Glucocorticoid Receptor Modulator Relacorilant in Combination with Nab-Paclitaxel

February 12, 2023

Lorusso et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022

Phase 1 Results of Exicorilant + Enzalutamide in Patients with Castration-Resistant Prostate Cancer

February 11, 2023

Linch et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022

Relacorilant + Nab-paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer: Phase 2 Subgroup Analysis Mirroring the Patient Population of an Upcoming Phase 3 Study

February 10, 2023

Colombo et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022